Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

MS is a disease of the nervous system. Many nerves have a myelin sheath — a protective layer that wraps around them and ...

One in three women will become pregnant after an MS diagnosis, therefore consideration of the maternal-infant dyad is needed.

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

Neurologist Stephen Hauser, MD, of the University of California San Francisco, and epidemiology professor Alberto Ascherio, ...

In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in ...

To date, I have no new lesions in my brain or spinal cord. Because, science met hope. Wrapped in love, from Sara without the ...

Piyush Goyal, the usually affable union minister of commerce and industry, has stirred a hornet’s nest with his comments ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Sarepta and Roche will share the monitors' findings with EMA to resolve a temporary hold. Elsewhere, Allakos agreed to a buyout and high-dose Ocrevus missed a study goal.

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...